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Abstract
Background: Low frequency (4–12 cpm) spontaneous fluctuations of the cerebrovascular tone (vasomotion) and
oscillations of the cerebral blood flow (CBF) have been reported in diseases associated with endothelial dysfunction. Since
endothelium-derived nitric oxide (NO) suppresses constitutively the release and vascular effects of thromboxane A2 (TXA2),
NO-deficiency is often associated with activation of thromboxane receptors (TP). In the present study we hypothesized that
in the absence of NO, overactivation of the TP-receptor mediated cerebrovascular signaling pathway contributes to the
development of vasomotion and CBF oscillations.
Methodology/Principal Findings: Effects of pharmacological modulation of TP-receptor activation and its downstream
signaling pathway have been investigated on CBF oscillations (measured by laser-Doppler flowmetry in anesthetized rats)
and vasomotion (measured by isometric tension recording in isolated rat middle cerebral arteries, MCAs) both under
physiological conditions and after acute inhibition of NO synthesis. Administration of the TP-receptor agonist U-46619
(1 mg/kg iv.) to control animals failed to induce any changes of the systemic or cerebral circulatory parameters. Inhibition of
the NO synthesis by nitro-L-arginine methyl esther (L-NAME, 100 mg/kg iv.) resulted in increased mean arterial blood
pressure and a decreased CBF accompanied by appearance of CBF-oscillations with a dominant frequency of 14862 mHz.
U-46619 significantly augmented the CBF-oscillations induced by L-NAME while inhibition of endogenous TXA2 synthesis by
ozagrel (10 mg/kg iv.) attenuated it. In isolated MCAs U-46619 in a concentration of 100 nM, which induced weak and
stable contraction under physiological conditions, evoked sustained vasomotion in the absence of NO, which effect could
be completely reversed by inhibition of Rho-kinase by 10 mM Y-27632.
Conclusion/Significance: These results suggest that hypersensitivity of the TP-receptor – Rho-kinase signaling pathway
contributes to the development of low frequency cerebral vasomotion which may propagate to vasospasm in
pathophysiological states associated with NO-deficiency.
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Introduction
Low frequency (4–12 cpm) fluctuations of the cerebral oxygen
availability in mammals were reported for the first time by Davis
and Bronk in 1957 [1] and confirmed later in primates including
humans (for review see: [2]). These fluctuations are termed
‘‘spontaneous’’ to indicate their independence of cardiac or
respiratory cycles. In 1981 Do ´ra and Kova ´ch [3] observed similar
oscillations in cerebrocortical NADH fluorescence, which lagged by
2 sec behind the cortical vascular volume suggesting that the
vascular event initiated the metabolic one. The concept that the low
frequency metabolic oscillations of the brain are induced primarily
by vascular changes and consequent variations of the cerebral blood
flow (CBF) is also supported by observations on isolated cerebral
vessels showing vasomotion in vitro [4–5]. Renewed interest in CBF
oscillations was generated by human studies using laser-Doppler
flowmetry [6–7], transcranial Doppler sonography [8], functional
MRI [9] and near infrared spectroscopy [10].
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oscillations has been reported in subarachnoid hemorrhage (SAH)
before the onset of cerebral vasospasm and during the recovery
from it [11]. This may indicate that overactivation of the
mechanism(s) responsible for vasomotion may also participate in
the pathogenesis of spastic vascular smooth muscle contractions
and, consequently, increased vasomotional activity may predict
the development of acute vasospasm. Contrary to this process,
vasodilation (induced by hypercapnia or volatile anesthetics)
promptly and reversibly suspends low frequency CBF oscillations
[12–13] and the cerebrovascular endothelium also suppresses
vasomotion by releasing nitric oxide (NO) [2]. In accordance,
enhanced CBF oscillations have been reported in pathophysiolog-
ical states associated with decreased bioavailability of NO, such as
SAH [11], traumatic brain injury [14] and hypertension [15].
Previous studies on isolated cerebral arteries implicated the
thromboxane pathway in the changes of vascular functions
following NO synthase (NOS) inhibition [5,16–17]. This interac-
tion is particularly interesting in the light of recent observations
indicating that in NO-deficiency other prostanoids (e.g. prostacy-
clin) may also induce vascular smooth muscle effects via activation
of the thromboxane (TP) receptor [18] and cerebrovascular
expression of TP-receptors is enhanced after SAH [19]. In the
present study we hypothesized that in the absence of NO
hypersensitivity of the cerebrovascular TP-receptor mediated
signaling pathway contributes to the enhanced vasomotion and
blood flow oscillations in the cerebral cortex.
Methods
The experiments were performed in adult male Wistar rats
(300–400 g) according to the guidelines of the Hungarian Law of
Animal Protection (243/1988) and all procedures were approved
by the Semmelweis University Committee on the Ethical Use of
Experimental Animals (590/99 Rh). The animals were anesthe-
tized with urethane (1.5 g/kg intraperitoneally), the depth of
anesthesia was regularly controlled during the experiments by
checking the corneal or plantar nociception reflex and additional
urethane was administered intravenously (iv.) as necessary. The
animals were spontaneously breathing through an intra-tracheal
cannula. Catheters were inserted into both femoral arteries (for
systemic arterial blood pressure measurement and for blood
sampling) and into the left femoral vein (for drug administration).
Body temperature was kept constant between 36–38uC with a
controlled heating pad.
Systemic arterial pressure was recorded continuously on a
polygraph (Model 7E, Grass, Quincy, MA, USA). Measurement of
cerebrocortical blood flow (CoBF) has been performed by laser-
Doppler (LD) flowmetry as described in detail elsewhere [20]. The
head of the animals was fixed in a stereotaxic head holder with the
nose 5 mm down from the interaural line. The skull of the parietal
region was exposed and the bone was thinned over the parietal
cortex on both sides with a microdrill, so that the lamina interna of
the skull remained intact. Two LD probes were placed above the
thinned skull at a 12u-angle to the vertical to provide an optimal
view of the cortex (4 mm caudal from bregma, 5 mm lateral from
midline). CoBF was measured with a two-channel blood flow
monitor (MBF3D, Moor Instruments, UK) and was recorded
continuously. The LD monitor was calibrated before each
individual experiment with a constant movement latex emulsion.
The laser light was in the infrared range (780 nm) and penetrated
about 1 mm into the brain covering approximately 7 mm
2 of the
parietal region, so that the data acquired mostly represented the
characteristics of the blood flow in the parietal cortex [20].
Animals were randomly assigned to four in vivo experimental
groups. In the control Group I. systemic and cerebral circulatory
parameters, as well as blood gas and acid-base values were
determined before as well as for 75 minutes after an iv. bolus
injection of 1 ml/kg vehicle (saline). Thereafter the animals
received the thromboxane receptor agonist U-46619 in a dose of
1 mg/kg iv., which in preliminary experiments was below the
threshold of inducing any systemic or cerebral circulatory changes.
Groups IIa., IIb. and IIc. received intravenously first N
G-nitro-L-
arginine methyl ester (L-NAME) in a dose of 100 mg/kg for the
inhibition of NO synthesis and 75 minutes later 1 mg/kg U-46619
(Group IIa.), saline (Group IIb.) or 10 mg/kg of the thromboxane
synthase inhibitor ozagrel (Group IIc.). Previous studies have
verified that L-NAME and ozagrel in the doses used in our present
study effectively inhibit the activity of cerebral NO synthase and
thromboxane synthase, respectively [21,22]. The final measure-
ments were performed in all experimental groups 50 minutes after
the administration of U-46619, saline or ozagrel.
The in vitro experiments were performed in middle cerebral
arteries (MCAs) supplying the parietal cortex, the site of the in vivo
CoBF measurements. MCA segments were prepared from adult
male Wistar rats and studied in a conventional myograph system
(610M, Danish Myo Technology A/S, Aarhus, Denmark) as
described previously [5,23]. First, each segment was exposed to
124 mmol/L K
+ Krebs solution to elicit a reference contraction.
After a 30-minute resting period, the functional integrity of the
endothelium was tested by application of bradykinin (0.01 to
10 mM) after precontraction induced by 100 mM UTP. Segments
that did not exhibit at least 20% relaxation of the precontraction
were considered to have damaged endothelium and were excluded
from the study. After a 30-minute resting period, during which the
baths were washed several times, the vessels received either
100 mM L-NAME in order to block NO synthesis or saline, the
vehicle of L-NAME. Fifteen minutes later the effects of 100 nM U-
46619 or 10 nM endothelin-1 (ET-1) were determined on the
vascular tension both in intact and NO synthase blocked vessels.
The role of Rho – Rho-kinase signaling pathway was tested by
administration of 10 mM Y-27632, a specific Rho-kinase inhibitor
[24], to NO synthase blocked vessels showing stable vasomotion
after administration of U-46619 or ET-1. In additional control
experiments intact MCA segments were precontracted with
25 mmol/L K
+ Krebs prior to administration of 100 nM U-
46619.
The Discrete Fourier transform (spectrum) of the time series
obtained in vivo (CoBF) or in vitro (vascular tone) was calculated
by Fast Fourier Algorithm (FFT) [25]. The calculations were
executed in the Matlab environment which uses an adaptive
version of the FFT, called FFTW [26]. The DC (zero frequency)
component was eliminated from the spectrum by subtracting the
mean value of time series from the samples and this way
generating zero-mean time series. In order to identify the largest
frequency component of the spectrum the region of interest was
gated by an appropriate frequency window.
Since CoBF oscillations could also be induced by simultaneous
changes of the blood pressure, we have performed the spectral
analysis of the blood pressure recordings with the same method as
described above. However, there was no difference in this
parameter either between or within the experimental groups.
All chemicals were obtained from Sigma-Aldrich (St. Louis,
MO, USA). Values are presented as mean 6 SEM; n represents
the number of experiments. Statistical analysis was performed
using repeated measures ANOVA followed by a Tukey post-hoc
test. A P value of less than 0.05 was considered to be statistically
significant.
TXA2 and NO in Vasomotion
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Baseline physiological parameters were within the normal range
in all in vivo experimental groups (Table 1.). Neither iv.
administration of saline nor that of the TP-receptor agonist U-
46619 in a dose of 1 mg/kg induced any significant changes in
acid-base, blood gas or systemic circulatory parameters in the
control Group I. (data not shown). Furthermore, neither the
average CoBF nor its Fourier spectrum changed after the
administration of saline or U-46619 in this experimental group
(data not shown). These observations confirmed that 1 mg/kg U-
46619 has no significant effect on the systemic and cerebrocortical
circulation under physiological conditions.
In the ‘‘NOS-blocked’’ Groups IIa., IIb. and IIc. iv.
administration of L-NAME had no significant effect on acid base
or blood gas parameters but increased systemic blood pressure and
decreased heart rate (Figure 1.). These changes developed within
25 minutes after L-NAME and remained unaltered later even
after the intravenous administration of 1 mg/kg U-46619 (in
Group Ia.), 1 ml/kg saline (in Group IIb.) or 10 mg/kg ozagrel (in
Group IIc.) (data not shown). The CoBF reduced by more than
25% within the first 25 min after L-NAME administration
(Figure 1.) but did not change further until the completion of
the experiments in any of these experimental groups (data not
shown). Low frequency CoBF oscillations, which were absent
under resting conditions, developed after the administration of L-
NAME with a dominant frequency of 14862 mHz and peak
magnitude of 5.660.5 AU (n=46). U-46619 significantly
increased while ozagrel decreased the magnitude of these
oscillations without changing the dominant frequency (Figure 2.).
In contrast, saline, the vehicle of U-46619 and ozagrel, failed to
induce any changes in the magnitude or frequency of CoBF
oscillations (Figure 2.).
In vitro experiments in isolated MCAs showed similar results to
the in vivo observations. In control vessels administration of saline
had no effect on the mean vascular tension while subsequent
administration of 100 nM U-46619 induced weak (10.965.3%)
vasoconstriction. In these vessels no vasomotion could be detected
before or after saline or U-46619, indicating that U-46619 in this
concentration fails to induce any vasomotional activity under
physiological conditions (data not shown).
Inhibition of the NO synthesis by L-NAME slightly increased
the vascular tone (by 9.562.2%) but did not induce vasomotion,
except in 3 vessels out of 32 in which the frequency of tension
oscillations was 67.2615.3 mHz. Subsequent stimulation of the
TP-receptors with 100 nM U-46619 induced significantly
(P,0.001) stronger elevation of the mean vascular tone (by
77.266.2%) as compared to the control vessels. Furthermore, U-
46619 which failed to induce any vasomotional activity in control
vessels, induced strong vasomotion in 16 out of 19 NOS-blocked
MCAs with a dominant frequency of 56.164.7 mHz. (The lower
frequency of these oscillations compared to those of the CoBF in
vivo is probably due to the larger diameter of MCAs as compared
to cerebral arterioles the resistance of which determines CoBF,
since it has been shown that the frequency of vasomotion is
negatively related to vessel diameter [27].) Quantitative analysis of
the peak magnitude of the Fourier spectra showed a 5.35-fold
increase after administration of U-46619 (Figure 3.). In 10 NOS-
blocked vessels showing strong vasomotion after U-46619, 10 mM
Y-27632 was applied in order to investigate the involvement of
Rho-kinase in the mediation of the vascular responses. In all of
these vessels Y-27632 abolished the vasoconstriction and vasomo-
tion (Figure 3.).
As mentioned earlier the mean vascular tension after L-
NAME+U-46619 treatment was significantly higher as compared
to the tension after saline+U-46619 (see above). Therefore, it could
be possible that the vasomotion-inducing effect of U-46619 in the
former vessels was due to the higher vascular tension and not due
to the absence of NO. In order to test this hypothesis in 13 control
vessels the vascular tone was increased by 25 mM K
+ prior to
administration 100 nM U-46619. No vasomotion has been
observed in any of these vessels athough their mean tension
(62.368.1%) was similar to that of the L-NAME+U-46619 treated
ones.
The above described results indicated that weak pharmacolog-
ical stimulation of TP-receptors, which induced negligible effects
under physiological conditions, evoked vasomotion and CoBF
oscillations in NO-deficiency. However, CoBF oscillation which
developed after inhibition of NO synthesis could not be reversed
completely by inhibition of TXA2 synthesis, raising the possibility
that other mediators may also be involved in this process.
Therefore, in further experiments we aimed to analyze if
endothelin-1, which reportedly also activates the Rho-kinase
signaling pathway in the cerebrovascular smooth muscle [28],
may also induce vasomotional activity in NOS-blocked MCAs. In
Table 1. Baseline physiological parameters in the different in
vivo experimental groups.
MESURED VARIABLE EXPERIMENTAL GROUP
I. IIa. IIb. IIc.
Mean Arterial Pressure
(mmHg)
97.962.4 100.062.9 97.763.5 107.764.0
Heart Rate (bpm) 410694 0 8 615 413684 3 5 620
PaCO2 (mmHg) 41.062.6 43.761.5 38.261.6 40.062.0
O2 Sat (%) 96.560.5 96.560.5 96.660.3 96.260.3
pH 7.3460.01 7.3260.02 7.3860.01 7.3760.01
Standard Base Excess
(mmol/l)
23.761.1 22.260.7 22.660.4 21.761.1
Values are mean 6 SEM (n=7, 10, 6 and 7 in Groups I, IIa., IIb. and IIc.,
respectively). No significant difference was found between the experimental
groups.
doi:10.1371/journal.pone.0014477.t001
Figure 1. NO synthase blockade increases mean arterial
pressure (MAP), while decreases heart rate (HR) and cerebro-
cortical blood flow (CoBF). Mean 6 SEM percentual changes are
shown after NO synthase inhibition by 100 mg/kg of L-NAME,
compared to the steady state pre-injection values presented on
Table 1 (n=10, 6 and 7 in the case of MAP and HR, and n=20, 12
and 14 in the case of CoBF in Groups IIa., IIb. and IIc., respectively).
doi:10.1371/journal.pone.0014477.g001
TXA2 and NO in Vasomotion
PLoS ONE | www.plosone.org 3 December 2010 | Volume 5 | Issue 12 | e1447710 out of 13 L-NAME pretreated vessels 10 nM endothelin-1
induced strong vasomotion with a dominant frequency of
48.867.3 mHz and it was reversible by Y-27632. Quantitatively,
the magnitude of the Fourier spectra showed a more than 5-fold
increase after administration of endothelin-1 which effect was
completely reversed by Y-27632 (Figure 3.). In contrast, adminis-
tration of 10 nM (or even 100 nM) endothelin-1 to 9 control vessels
failed to induce any vasomotional activity (data not shown).
Discussion
Our results indicate that activation of TP-receptors increases
cerebral vasomotion and CBF oscillations in NO-deficiency. This
observation is particularly interesting in the light of the high
prevalence of pathologic conditions associated with diminished
release and/or biological effectiveness of NO, such as atheroscle-
rosis, diabetes, hypertension, ischemia/reperfusion and SAH.
Since NO suppresses platelet aggregation as well as vascular
release of TXA2, NO-deficiency is often associated with activation
of TP-receptors. Therefore, experimental conditions of the present
study mimicked features of several cerebrovascular diseases.
Vasomotion is often enhanced in these pathophysiological states
although it is still a question of debate whether CBF oscillations
represent the last attempt of the cerebral circulation to prevent
neuronal hypoxia or it is already the first sign of the already
disrupted regulation. Both of these interpretations can be
supported by the observations that CoBF oscillations precede the
onset of vasospasm in SAH [11].
NO reportedly suppresses the synthesis of TXA2 [29] and
inhibition of NOS was recently reported to enhance TXA2 release
Figure 2. Weak activation of thromboxane receptors aggravates while inhibition of TXA2 synthesis attenuates CoBF oscillations
developed in the absence of NO. A–C: Original recordings of the cerebrocortical laser-Doppler flux in vivo before (left panels) and after (right
panels) administration of the TP-receptor agonist U-46619 (A), the thromboxane synthase inhibitor ozagrel (C) or their vehicle (saline) (B) in rats
pretreated by the NO synthase inhibitor L-NAME. D: Quantitative analysis of slow wave oscillations with discrete Fourier transformation. The peak
magnitudes of the power spectra are compared before and after treatments in the three experimental groups. Values are mean 6 SEM (n=20, 12 and
14 in Group IIa, IIb, and IIc, respectively) *p,0.05 vs. ‘‘Before Treatment’’.
doi:10.1371/journal.pone.0014477.g002
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that ozagrel inhibited L-NAME induced CoBF oscillations clearly
indicates that endogenous TXA2 significantly contributes to the
development of cerebral vasomotion in NO-deficiency. On the
other hand, the cerebrovascular endothelium is not likely to be the
only source of TXA2 release since L-NAME induced vasomotion
in only 3 out of 32 isolated MCAs in vitro, suggesting that vascular
TXA2 production by itself may not be sufficient to evoke
vasomotion even in case of diminished NO synthesis. However,
stimulation of the TP-receptors by 100 nM U-46619, which was
without any effect under physiological conditions, induced strong
vasomotion in the absence of NO indicating a hypersensitivity of
the vessels to TXA2. Since this effect developed at a constant level
of TP-receptor stimulation fluctuations of the cerebrovascular tone
and CoBF appear to be rather potentiated but not directly induced
by TP-receptor mediated mechanisms.
In a recent study we have shown that both the Gq/11 and the
G12/13 heterotrimeric G proteins are involved in the mediation of
TXA2-induced vasoconstriction [30]. However, the vascular
effects of weak TP-receptor stimulation, like those applied in
the present study, are primarily induced by the G12/13-mediated
activation of the small G protein RhoA and Rho-kinase (Ne ´meth
and Benyo ´, unpublished observations), the main signaling
pathway of calcium-sensitization. Since vasomotion is induced
by calcium waves in the smooth muscle [31], TP-receptor
mediated calcium-sensitization can enhance the resultant changes
of the vascular tension, which is the most plausible explanation of
our findings.
Why is this TP-receptor mediated mechanism enhanced in NO-
deficiency? As noted above, the increased release of endogenous
TXA2 can only partly explain our observations. In the cerebral
circulation constitutive NO-synthesis maintains a basal vasodilator
tone, partly by inhibition of the vasoconstrictor TXA2-pathway
[16]. TP-receptors are targets of cyclic GMP-dependent kinase
(PKG) which induce desensitization by phosphorylation at Ser
331
of the C-tail domain of the receptor [32–33]. Furthermore, NO
also interferes with the signaling pathway coupling TP-receptor
activation to vascular smooth muscle contraction. For instance,
NO reportedly inhibits calcium sensitization by PKG-mediated
inhibition of RhoA [34–35] and telokin [36], as well as by
inhibition of RhoA activation through protein kinase A (PKA)-
dependent phosphorylation of Ga13 [37]. PKG can also inhibit
calcium sensitization by phosphorylating directly the myosin
phosphatase targeting subunit (MYPT1) at Ser
695, resulting in
the reduction of phosphorylation at the adjacent inhibitory Thr
696
site [38–40], the target of Rho-kinase [41]. Therefore, in the
absence of NO not only the TP-receptors but also these
downstream signaling pathways will be released from the tonic
inhibitory influence of NO resulting in a sensitized smooth muscle
contractile machinery to fluctuations induced by calcium waves.
Indeed, in our present study, inhibition of Rho-kinase by Y-27632
completely reversed the vasomotion induced by U-46619 in NO
synthase blocked MCAs.
Activation of the RhoA – Rho-kinase pathway has been recently
implicated as a key signaling mechanism in the development of
several cerebrovascular disorders [42]. TXA2 is one but not the
only activator of this signaling pathway in the cerebrovascular
smooth muscle which conclusion is also supported by our
observations that inhibition of the thromboxane-synthesis could
only partially reverse the CoBF oscillations after NO synthase
blockade while Y-27632 completely abolished vasomotion in vitro.
It has been recently demonstrated that endothelin-1, already at
low concentrations, activates the RhoA – Rho-kinase pathway in
the cerebrovascular smooth muscle [28]. Although we didn’t
provide direct evidence for its involvement in the generation of
CoBF oscillations in vivo, our in vitro data that in NO-deficiency
endothelin-1 induces Y-27632 reversible vasomotion supports this
hypothesis.
In conclusion, our results indicate that both endogenous TXA2
production and hypersensitivity of the TP-receptors and/or the
Rho-kinase signaling pathway in the cerebrovascular smooth
muscle contribute to the development of CBF oscillations after NO
synthase blockade. Pharmacological inhibition of this enhanced
reactivity may be beneficial to prevent vasospasm in cerebrovas-
cular disorders associated with NO-deficiency.
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